MAPK9(JNK2)
Sign in to save this workspaceUniProt P45984-1 · PDB · AlphaFold · Substrate: ATF2 · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Neratinib | 68.4% | 31.6% | 93.18 | 0.597 |
| 2 | Encorafenib | 65.6% | 34.4% | 98.50 | 0.755 |
| 3 | Ponatinib | 56.9% | 43.1% | 78.23 | 0.534 |
| 4 | Brigatinib | 48.8% | 51.2% | 82.96 | 0.513 |
| 5 | Ripretinib | 48.7% | 51.3% | 92.95 | 0.674 |
| 6 | Fostamatinib | 39.5% | 60.5% | 96.74 | 0.613 |
| 7 | Gilteritinib | 34.4% | 65.6% | 88.97 | 0.506 |
| 8 | Fedratinib | 30.8% | 69.2% | 96.21 | 0.576 |
| 9 | Abemaciclib | 25.8% | 74.2% | 91.48 | 0.563 |
| 10 | Pacritinib | 24.0% | 76.0% | 88.64 | 0.452 |
| 11 | Apatinib | 20.5% | 79.5% | 97.73 | 0.704 |
| 12 | Umbralisib | 20.0% | 80.0% | 98.74 | 0.670 |
| 13 | Defactinib | 16.7% | 83.3% | 92.68 | 0.450 |
| 14 | Canertinib | 15.5% | 84.5% | 96.49 | 0.671 |
| 15 | Pazopanib | 15.2% | 84.8% | 97.49 | 0.672 |
| 16 | Palbociclib | 14.6% | 85.4% | 98.75 | 0.673 |
| 17 | Dacomitinib | 14.3% | 85.7% | 97.99 | 0.664 |
| 18 | Leniolisib | 13.5% | 86.5% | 100.00 | 0.604 |
| 19 | Alectinib | 12.8% | 87.2% | 95.49 | 0.651 |
| 20 | Selumetinib | 11.2% | 88.8% | 100.00 | 0.640 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.58
- Epithelial log2(TPM+1): 4.56
- Fold change: 0.01
- Status: No significant change
Selectivity landscape vs inhibition on MAPK9
Each point is one of the 92 approved drugs; color = inhibition % on MAPK9.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…